{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:23:44Z","timestamp":1740173024747,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aims to compare the accuracy of mean GH profile (GHP) &lt;\u20092.5\u00a0ng\/ml and single fasting GH (SGH) &lt;\u20091\u00a0ng\/ml in the evaluation of disease control in acromegaly patients during somatostatin receptor ligands (SRLs) therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively enrolled 100 acromegaly patients, 68 responder, and 32 partial responder to SRLs. Controlled disease has been defined as IGF-I levels within age-related normal limits, while partial response as pathological IGF-I values despite a reduction \u2265\u200950%. In all patients, GHP, SGH, IGF-I, and IGFBP-3 were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median GHP levels (1.2\u00a0ng\/ml, IQR 0.5\u20132.3\u00a0ng\/ml) were lower (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) than SGH (1.9\u00a0ng\/ml, IQR 1.0\u20133.6\u00a0ng\/ml). Accuracy of GHP was 81%, whereas that of SGH was 55%, with a Kappa index of 0.520 and 0.237, respectively. In multivariable analysis GHP (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) and IGFBP-3 (<jats:italic>p<\/jats:italic>\u2009=\u20090.004), but not SGH, were independently associated with normal IGF-I levels. At receiver\u2013operator characteristic curve (ROC) analysis GHP cut-off sensitivity and specificity were 94.1% and 50.0%, respectively, while SGH sensitivity and specificity were 35.3% and 93.7%, respectively. Finally, in obese patients the GH cut-off level (both as SGH and GHP) associated to good disease control was significantly different with respect to not obese ones.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>GHP associates with IGF-I (and therefore with appropriate control of disease) with higher accuracy than SGH. When GH evaluation is needed, the measurement of mean GHP should be preferred and use of BMI-related cut-offs is suggested.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-022-01830-6","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T05:02:51Z","timestamp":1656046971000},"page":"1955-1965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-2335","authenticated-orcid":false,"given":"C.","family":"Bona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Prencipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Berton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bioletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Parasiliti-Caprino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grottoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"1830_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667\u2013674. https:\/\/doi.org\/10.1210\/jc.2003-031199","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EJE-08-0267","volume":"159","author":"IM Holdaway","year":"2008","unstructured":"Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89\u201395. https:\/\/doi.org\/10.1530\/EJE-08-0267","journal-title":"Eur J Endocrinol"},{"key":"1830_CR3","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1210\/jc.2003-032041","volume":"89","author":"NR Biermasz","year":"2004","unstructured":"Biermasz NR, Dekker FW, Pereira AM et al (2004) Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789\u20132796. https:\/\/doi.org\/10.1210\/jc.2003-032041","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR4","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1210\/jcem.83.10.5222","volume":"83","author":"B Swearingen","year":"1998","unstructured":"Swearingen B, Barker FG, Katznelson L et al (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419\u20133426. https:\/\/doi.org\/10.1210\/jcem.83.10.5222","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/jc.2007-1191","volume":"93","author":"OM Dekkers","year":"2008","unstructured":"Dekkers OM, Biermasz NR, Pereira AM et al (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61\u201367. https:\/\/doi.org\/10.1210\/jc.2007-1191","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR6","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1210\/jc.2003-031584","volume":"89","author":"J Ayuk","year":"2004","unstructured":"Ayuk J, Clayton RN, Holder G et al (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613\u20131617. https:\/\/doi.org\/10.1210\/jc.2003-031584","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR7","first-page":"293","volume":"86","author":"AS Bates","year":"1993","unstructured":"Bates AS, Van Hoff W, Jones JM, Clayton RN (1993) An audit of outcome of treatment in acromegaly. Q J Med 86:293\u2013299","journal-title":"Q J Med"},{"key":"1830_CR8","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1210\/jcem.83.8.5007","volume":"83","author":"SM Orme","year":"1998","unstructured":"Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730\u20132734. https:\/\/doi.org\/10.1210\/jcem.83.8.5007","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/0002-9343(94)90327-1","volume":"97","author":"Acromegaly Therapy Consensus Development Panel","year":"1994","unstructured":"Acromegaly Therapy Consensus Development Panel (1994) Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med 97:468\u2013473. https:\/\/doi.org\/10.1016\/0002-9343(94)90327-1","journal-title":"Am J Med"},{"key":"1830_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/j.1365-2265.1995.tb02913.x","volume":"43","author":"D Jenkins","year":"1995","unstructured":"Jenkins D, O\u2019Brien I, Johnson A et al (1995) The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol (Oxf) 43:517\u2013522. https:\/\/doi.org\/10.1111\/j.1365-2265.1995.tb02913.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1830_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1210\/jcem.85.2.6363","volume":"85","author":"A Giustina","year":"2000","unstructured":"Giustina A, Barkan A, Casanueva FF et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526\u2013529. https:\/\/doi.org\/10.1210\/jcem.85.2.6363","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1530\/eje.1.02036","volume":"153","author":"S Melmed","year":"2005","unstructured":"Melmed S, Casanueva F, Cavagnini F et al (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737\u2013740. https:\/\/doi.org\/10.1530\/eje.1.02036","journal-title":"Eur J Endocrinol"},{"key":"1830_CR13","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"94","author":"S Melmed","year":"2009","unstructured":"Melmed S, Colao A, Barkan A et al (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509\u20131517. https:\/\/doi.org\/10.1210\/jc.2008-2421","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR14","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141\u20133148. https:\/\/doi.org\/10.1210\/jc.2009-2670","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR15","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR16","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C et al (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769\u20134775. https:\/\/doi.org\/10.1210\/jc.2006-1668","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1210\/jc.2007-2104","volume":"93","author":"O Alexopoulou","year":"2008","unstructured":"Alexopoulou O, Bex M, Abs R et al (2008) Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93:1324\u20131330. https:\/\/doi.org\/10.1210\/jc.2007-2104","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR18","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1210\/jc.2004-1974","volume":"90","author":"CL Ronchi","year":"2005","unstructured":"Ronchi CL, Varca V, Giavoli C et al (2005) Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 90:1377\u20131382. https:\/\/doi.org\/10.1210\/jc.2004-1974","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ghir.2008.02.001","volume":"18","author":"EO Machado","year":"2008","unstructured":"Machado EO, Taboada GF, Neto LV et al (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 18:389\u2013393. https:\/\/doi.org\/10.1016\/j.ghir.2008.02.001","journal-title":"Growth Horm IGF Res"},{"key":"1830_CR20","doi-asserted-by":"publisher","first-page":"618","DOI":"10.20945\/2359-3997000000192","volume":"63","author":"K Schilbach","year":"2019","unstructured":"Schilbach K, Bidlingmaier M (2019) Laboratory investigations in the diagnosis and follow-up of GH-related disorders. Arch Endocrinol Metab 63:618\u2013629. https:\/\/doi.org\/10.20945\/2359-3997000000192","journal-title":"Arch Endocrinol Metab"},{"key":"1830_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-10-0969","volume":"164","author":"SJ Neggers","year":"2011","unstructured":"Neggers SJ, Kopchick JJ, J\u00f8rgensen JOL, van der Lely AJ (2011) Hypothesis: extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol 164:11\u201316. https:\/\/doi.org\/10.1530\/EJE-10-0969","journal-title":"Eur J Endocrinol"},{"key":"1830_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","volume":"179","author":"F Bolfi","year":"2018","unstructured":"Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS (2018) Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 179:59\u201371. https:\/\/doi.org\/10.1530\/EJE-18-0255","journal-title":"Eur J Endocrinol"},{"key":"1830_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1210\/jc.2007-1451","volume":"93","author":"K BajukStuden","year":"2008","unstructured":"BajukStuden K, Barkan A (2008) Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models. J Clin Endocrinol Metab 93:491\u2013496. https:\/\/doi.org\/10.1210\/jc.2007-1451","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/cen.13129","volume":"85","author":"GA Kanakis","year":"2016","unstructured":"Kanakis GA, Chrisoulidou A, Bargiota A et al (2016) The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 85:681\u2013688. https:\/\/doi.org\/10.1111\/cen.13129","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1830_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1210\/jc.2008-1371","volume":"94","author":"JD Carmichael","year":"2009","unstructured":"Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94:523\u2013527. https:\/\/doi.org\/10.1210\/jc.2008-1371","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR26","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/BF03345307","volume":"27","author":"R Cozzi","year":"2004","unstructured":"Cozzi R, Attanasio R, Grottoli S et al (2004) Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? J Endocrinol Invest 27:1040\u20131047. https:\/\/doi.org\/10.1007\/BF03345307","journal-title":"J Endocrinol Invest"},{"key":"1830_CR27","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/clinem\/dgaa859","volume":"106","author":"C Campana","year":"2021","unstructured":"Campana C, Cocchiara F, Corica G et al (2021) Discordant GH and IGF-1 results in treated acromegaly: impact of GH cutoffs and mean values assessment. J Clin Endocrinol Metab 106:789\u2013801. https:\/\/doi.org\/10.1210\/clinem\/dgaa859","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1530\/eje.0.1500465","volume":"150","author":"S Gullu","year":"2004","unstructured":"Gullu S, Keles H, Delibasi T et al (2004) Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol 150:465\u2013471. https:\/\/doi.org\/10.1530\/eje.0.1500465","journal-title":"Eur J Endocrinol"},{"key":"1830_CR29","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1210\/jc.2004-2009","volume":"90","author":"JJ Puder","year":"2005","unstructured":"Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90:1972\u20131978. https:\/\/doi.org\/10.1210\/jc.2004-2009","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1023\/b:pitu.0000011174.79946.10","volume":"6","author":"PU Freda","year":"2003","unstructured":"Freda PU (2003) Pitfalls in the biochemical assessment of acromegaly. Pituitary 6:135\u2013140. https:\/\/doi.org\/10.1023\/b:pitu.0000011174.79946.10","journal-title":"Pituitary"},{"key":"1830_CR31","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1210\/jcem.87.8.8658","volume":"87","author":"EV Dimaraki","year":"2002","unstructured":"Dimaraki EV, Jaffe CA, DeMott-Friberg R et al (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537\u20133542. https:\/\/doi.org\/10.1210\/jcem.87.8.8658","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR32","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1210\/jc.2009-2634","volume":"95","author":"AT Faje","year":"2010","unstructured":"Faje AT, Barkan AL (2010) Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 95:2486\u20132491. https:\/\/doi.org\/10.1210\/jc.2009-2634","journal-title":"J Clin Endocrinol Metab"},{"key":"1830_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ghir.2006.12.003","volume":"17","author":"GF Taboada","year":"2007","unstructured":"Taboada GF, Correa LL, de Oliveira ME et al (2007) Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR. Growth Horm IGF Res 17:77\u201381. https:\/\/doi.org\/10.1016\/j.ghir.2006.12.003","journal-title":"Growth Horm IGF Res"},{"key":"1830_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1530\/EJE-19-0139","volume":"181","author":"K Schilbach","year":"2019","unstructured":"Schilbach K, Gar C, Lechner A et al (2019) Determinants of the growth hormone nadir during oral glucose tolerance test in adults. Eur J Endocrinol 181:55\u201367. https:\/\/doi.org\/10.1530\/EJE-19-0139","journal-title":"Eur J Endocrinol"},{"key":"1830_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1053\/meta.2003.50036","volume":"52","author":"H Vierhapper","year":"2003","unstructured":"Vierhapper H, Heinze G, Gessl A et al (2003) Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 52:181\u2013185. https:\/\/doi.org\/10.1053\/meta.2003.50036","journal-title":"Metabolism"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01830-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01830-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01830-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T14:00:21Z","timestamp":1662732021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01830-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01830-6","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was conducted according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association and that it was approved by the Ethics Committee of the \u201cA.O.U. Citt\u00e0 della Salute e della Scienza\u201d, University Hospital of Turin.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"All subjects gave their informed consent to participate.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}